Seroatlas · Human Serome Atlas

LHCGR

Lutropin-choriogonadotropic hormone receptor

Also known as: HHG, LCGR, LGR2, LHR, LSHR_HUMAN, ULG5

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
P22888
Gene
LHCGR
Ensembl
ENSG00000138039
Chromosome
2
Canonical length
699 aa
Protein class
Disease related genes, FDA approved drug targets, G-protein coupled receptors, Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins
Subcellular location
Plasma membrane,Centriolar satellite

OverviewNCBI Gene

This gene encodes the receptor for both luteinizing hormone and choriogonadotropin. This receptor belongs to the G-protein coupled receptor 1 family, and its activity is mediated by G proteins which activate adenylate cyclase. Mutations in this gene result in disorders of male secondary sexual character development, including familial male precocious puberty, also known as testotoxicosis, hypogonadotropic hypogonadism, Leydig cell adenoma with precocious puberty, and male pseudohermaphtoditism with Leydig cell hypoplasia. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

699 residues, UniProt reviewed canonical sequence.

>P22888|LHCGR
     1  MKQRFSALQL LKLLLLLQPP LPRALREALC PEPCNCVPDG ALRCPGPTAG LTRLSLAYLP
    61  VKVIPSQAFR GLNEVIKIEI SQIDSLERIE ANAFDNLLNL SEILIQNTKN LRYIEPGAFI
   121  NLPRLKYLSI CNTGIRKFPD VTKVFSSESN FILEICDNLH ITTIPGNAFQ GMNNESVTLK
   181  LYGNGFEEVQ SHAFNGTTLT SLELKENVHL EKMHNGAFRG ATGPKTLDIS STKLQALPSY
   241  GLESIQRLIA TSSYSLKKLP SRETFVNLLE ATLTYPSHCC AFRNLPTKEQ NFSHSISENF
   301  SKQCESTVRK VNNKTLYSSM LAESELSGWD YEYGFCLPKT PRCAPEPDAF NPCEDIMGYD
   361  FLRVLIWLIN ILAIMGNMTV LFVLLTSRYK LTVPRFLMCN LSFADFCMGL YLLLIASVDS
   421  QTKGQYYNHA IDWQTGSGCS TAGFFTVFAS ELSVYTLTVI TLERWHTITY AIHLDQKLRL
   481  RHAILIMLGG WLFSSLIAML PLVGVSNYMK VSICFPMDVE TTLSQVYILT ILILNVVAFF
   541  IICACYIKIY FAVRNPELMA TNKDTKIAKK MAILIFTDFT CMAPISFFAI SAAFKVPLIT
   601  VTNSKVLLVL FYPINSCANP FLYAIFTKTF QRDFFLLLSK FGCCKRRAEL YRRKDFSAYT
   661  SNCKNGFTGS NKPSQSTLKL STLHCQGTAL LDKTRYTEC

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against LHCGR can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Cell surface
Secreted
No
Transmembrane segments
7
Mean surface accessibility (rSASA)
0.32
Highest tissue expression
2.1 nTPM

Expression across tissuesHPA

Tissue

  • ovary: 2.1 nTPM
  • testis: 2.1 nTPM
  • adipose tissue: 1.2 nTPM
  • adrenal gland: 0.8 nTPM
  • breast: 0.7 nTPM
  • thyroid gland: 0.6 nTPM

Single-cell type

  • adipocytes: 3.4 nCPM
  • corticotrophs: 0.5 nCPM
  • pituicytes/fscs: 0.3 nCPM
  • fibroblasts: 0.2 nCPM
  • hofbauer cells: 0.2 nCPM
  • innate lymphoid cells: 0.2 nCPM

Immune cell

  • basophil: 0 nTPM
  • classical monocyte: 0 nTPM
  • eosinophil: 0 nTPM
  • gdT-cell: 0 nTPM
  • intermediate monocyte: 0 nTPM
  • MAIT T-cell: 0 nTPM

Brain region

  • medulla oblongata: 6.1 nTPM
  • spinal cord: 3.1 nTPM
  • white matter: 2.8 nTPM
  • pons: 1.9 nTPM
  • cerebellum: 1.7 nTPM
  • hypothalamus: 1.7 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about LHCGR.

Disease | AllUniProt

Conditions LHCGR is implicated in, by any mechanism.

Disease | GeneticClinVar

55 pathogenic / likely-pathogenic of 317 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.89
gnomAD pLI
0
gnomAD missense Z
0.16
DepMap mean gene effect
0.08
DepMap dependency class
none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of LHCGR in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads LHCGR as an antibody target. Whether an autoantibody or antibody against LHCGR could matter depends on whether native LHCGR is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

LHCGR is annotated at the cell surface, where native LHCGR is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label LHCGR as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/LHCGR. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

Loading the interactive Seroatlas protein explorer...